Table 4. Disease-free and overall survivals in the total entire population and subgroups.

			Disease-free survival				Overall survival
	No.		Median (months)				Median (months)
	GEM	Surgery-only	GEM	Surgery-only	HR (95% CI)	P-value	GEM	Surgery-only	HR (95% CI)	P-value
All patients	58	60	11.4	5.0	0.60 (0.40–0.89)	0.01	22.3	18.4	0.77 (0.51–1.14)	0.19
R0	47	52	11.4	5.1	0.58 (0.37–0.91)	0.02	26.8	19.1	0.70 (0.45–1.09)	0.11
R1	11	8	9.5	3.4	0.39 (0.15–1.06)	0.05	18.3	17.6	1.05 (0.41–2.72)	0.92
N0	19	18	—	9.0	0.38 (0.16–0.86)	0.02	32.0	28.4	0.63 (0.29–1.37)	0.24
N1	39	42	8.6	4.5	0.73 (0.46–1.16)	0.19	17.1	17.3	0.84 (0.53–1.34)	0.84
Stage I–II	13	14	—	10.0	0.27 (0.08–0.85)	0.02	67.8	—	0.42 (0.15–1.22)	0.10
Stage III–IV	45	46	8.9	4.6	0.68 (0.44–1.05)	0.08	18.3	16.3	0.82 (0.53–1.26)	0.36

Abbreviations: CI=confidence interval; GEM=gemcitabine; HR=hazard ratio.